{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peripheral+Blood&page=2", "query": { "intervention": "Peripheral Blood", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peripheral+Blood&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-20T12:22:24.024Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02519322", "title": "Neoadjuvant and Adjuvant Checkpoint Blockade", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous Melanoma", "Mucosal Melanoma", "Ocular Melanoma", "Stage III Acral Lentiginous Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIB Uveal Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IIIC Uveal Melanoma AJCC v7", "Stage IV Acral Lentiginous Melanoma AJCC v6 and v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Stage IV Uveal Melanoma AJCC v7" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Relatlimab", "type": "BIOLOGICAL" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2016-02-02", "completion_date": "2023-01-26", "has_results": true, "last_update_posted_date": "2024-04-05", "last_synced_at": "2026-09-20T12:22:24.024Z", "location_count": 2, "location_summary": "New York, New York • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02519322" }, { "nct_id": "NCT01334502", "title": "Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "everolimus", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2012-03", "completion_date": "2017-08", "has_results": false, "last_update_posted_date": "2017-08-10", "last_synced_at": "2026-09-20T12:22:24.024Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01334502" }, { "nct_id": "NCT01030445", "title": "Cardiac Function as Measured by Non-invasive Electrical Velocimetry Cardiac Monitor in Hospitalized Children", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cardiac Output", "Blood Pressure" ], "interventions": [], "intervention_types": [], "sponsor": "Boston Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 83, "start_date": "2009-12", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2017-01-05", "last_synced_at": "2026-09-20T12:22:24.024Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01030445" }, { "nct_id": "NCT02035527", "title": "Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Salivary Gland Squamous Cell Carcinoma", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IVA Salivary Gland Cancer", "Stage IVA Squamous Cell Carcinoma of the Larynx", "Stage IVA Oral Cavity Squamous Cell Carcinoma", "Stage IVA Squamous Cell Carcinoma of the Oropharynx", "Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Verrucous Carcinoma of the Larynx", "Stage IVA Verrucous Carcinoma of the Oral Cavity", "Stage IVB Salivary Gland Cancer", "Stage IVB Squamous Cell Carcinoma of the Larynx", "Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVB Squamous Cell Carcinoma of the Oropharynx", "Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Verrucous Carcinoma of the Larynx", "Stage IVB Verrucous Carcinoma of the Oral Cavity", "Stage IVC Salivary Gland Cancer", "Stage IVC Squamous Cell Carcinoma of the Larynx", "Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVC Squamous Cell Carcinoma of the Oropharynx", "Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Verrucous Carcinoma of the Larynx", "Stage IVC Verrucous Carcinoma of the Oral Cavity", "Tongue Cancer", "Untreated Metastatic Squamous Neck Cancer With Occult Primary" ], "interventions": [ { "name": "sorafenib tosylate", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "Correlative Studies", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2014-04-14", "completion_date": "2017-04-20", "has_results": false, "last_update_posted_date": "2018-05-24", "last_synced_at": "2026-09-20T12:22:24.024Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02035527" }, { "nct_id": "NCT00332761", "title": "Caduet in an Untreated Subject Population", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hypertension", "Dyslipidemia" ], "interventions": [ { "name": "Caduet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 220, "start_date": "2006-06", "completion_date": "2007-09", "has_results": false, "last_update_posted_date": "2021-01-27", "last_synced_at": "2026-09-20T12:22:24.024Z", "location_count": 34, "location_summary": "Jonesboro, Arkansas • Little Rock, Arkansas • Garden Grove, California + 30 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Garden Grove", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Tustin", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00332761" }, { "nct_id": "NCT03546686", "title": "Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Core Biopsy/Cryoablation", "type": "PROCEDURE" }, { "name": "Breast Surgery", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 51, "start_date": "2019-11-12", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-09-20T12:22:24.024Z", "location_count": 4, "location_summary": "Los Angeles, California • Columbus, Ohio • Portland, Oregon + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03546686" }, { "nct_id": "NCT00148070", "title": "Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Erythromycin Breath Test (ERMBT)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 45, "start_date": "1999-03", "completion_date": "2006-02", "has_results": false, "last_update_posted_date": "2012-10-05", "last_synced_at": "2026-09-20T12:22:24.024Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00148070" }, { "nct_id": "NCT03440970", "title": "Mechanism and Effects of Manipulating Chloride Homeostasis in Stable Heart Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Decompensated Heart Failure" ], "interventions": [ { "name": "Lysine Chloride", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2019-01-15", "completion_date": "2025-08-30", "has_results": false, "last_update_posted_date": "2025-09-15", "last_synced_at": "2026-09-20T12:22:24.024Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03440970" }, { "nct_id": "NCT00001741", "title": "Study of Inherited Changes of Receptors Located on Blood Vessels", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cardiovascular Disease" ], "interventions": [ { "name": "Losartan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 200, "start_date": "1997-11", "completion_date": "2003-04", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-09-20T12:22:24.024Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001741" }, { "nct_id": "NCT01175356", "title": "Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ganglioneuroblastoma", "Localized Resectable Neuroblastoma", "Localized Unresectable Neuroblastoma", "Regional Neuroblastoma", "Stage 4 Neuroblastoma", "Stage 4S Neuroblastoma" ], "interventions": [ { "name": "3-Dimensional Conformal Radiation Therapy", "type": "RADIATION" }, { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide Phosphate", "type": "DRUG" }, { "name": "External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "In Vitro-Treated Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Iobenguane I-131", "type": "RADIATION" }, { "name": "Isotretinoin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Topotecan Hydrochloride", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 99, "start_date": "2011-12-21", "completion_date": "2025-12-31", "has_results": true, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-09-20T12:22:24.024Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01175356" } ] }